Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
brentuximab vedotin is an approved drug (FDA (2011), EMA (2012))
Compound class:
Antibody
Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2011), EMA (2012)) |
International Nonproprietary Names | |
INN number | INN |
9144 | brentuximab vedotin |
Synonyms |
Adcetris® | anti-CD30 ADC SGN-35 | SGN 35 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 324 |
Other databases | |
GtoPdb PubChem SID | 178103378 |
PubChem SID | 178103378 |
Search PubMed clinical trials | brentuximab vedotin |
Search PubMed titles | brentuximab vedotin |
Search PubMed titles/abstracts | brentuximab vedotin |
Wikipedia | Brentuximab_vedotin |